Liji Shen
About
Liji Shen is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Liji Shen has authored 37 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 12 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Liji Shen's work include Prostate Cancer Treatment and Research (19 papers), Cancer Treatment and Pharmacology (12 papers) and Radiopharmaceutical Chemistry and Applications (10 papers). Liji Shen is often cited by papers focused on Prostate Cancer Treatment and Research (19 papers), Cancer Treatment and Pharmacology (12 papers) and Radiopharmaceutical Chemistry and Applications (10 papers). Liji Shen collaborates with scholars based in United States, France and United Kingdom. Liji Shen's co-authors include Oliver Sartor, Johann S. de Bono, Stéphane Oudard, Steinbjørn Hansen, Mustafa Özgüroğlu, Gwénaëlle Gravis, Ivo Kocák, I. Bodrogi, Mary J. MacKenzie and Sunil Gupta and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.
In The Last Decade
Liji Shen
34 papers receiving 3.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Liji Shen United States | 16 | 2.8k | 1.3k | 1.1k | 946 | 620 | 37 | 3.5k | ||
| Ivo Kocák Czechia | 13 | 2.5k 0.9× | 1.4k 1.1× | 937 0.8× | 798 0.8× | 724 1.2× | 41 | 3.3k | ||
| Susan Feyerabend United Kingdom | 21 | 3.2k 1.1× | 1.0k 0.8× | 1.0k 0.9× | 1.1k 1.2× | 726 1.2× | 71 | 3.9k | ||
| J Horti Hungary | 9 | 3.6k 1.3× | 1.6k 1.3× | 1.2k 1.1× | 1.1k 1.1× | 1.0k 1.6× | 17 | 4.6k | ||
| Peter De Porre United States | 26 | 2.5k 0.9× | 761 0.6× | 893 0.8× | 854 0.9× | 730 1.2× | 91 | 3.4k | ||
| Bryan Selby United States | 5 | 3.3k 1.2× | 917 0.7× | 1.1k 1.0× | 1.0k 1.1× | 848 1.4× | 11 | 3.7k | ||
| Matthew M. Cooney United States | 24 | 3.6k 1.3× | 1.8k 1.4× | 1.1k 1.0× | 1.1k 1.2× | 1.0k 1.7× | 86 | 5.2k | ||
| William R. Berry United States | 11 | 3.9k 1.4× | 1.8k 1.4× | 1.3k 1.1× | 1.1k 1.2× | 985 1.6× | 22 | 4.9k | ||
| Mary Ellen Taplin United States | 16 | 4.2k 1.5× | 1.6k 1.2× | 962 0.9× | 1.0k 1.1× | 924 1.5× | 27 | 5.1k | ||
| Luis Fein Argentina | 18 | 2.6k 0.9× | 1.7k 1.3× | 727 0.7× | 1.3k 1.4× | 530 0.9× | 52 | 3.8k | ||
| David Lorente Spain | 28 | 1.8k 0.7× | 1.2k 0.9× | 653 0.6× | 1.1k 1.1× | 594 1.0× | 100 | 2.9k |
Countries citing papers authored by Liji Shen
Since
Specialization
Citations
This map shows the geographic impact of Liji Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liji Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liji Shen more than expected).
Fields of papers citing papers by Liji Shen
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Liji Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liji Shen. The network helps show where Liji Shen may publish in the future.
Co-authorship network of co-authors of Liji Shen
This figure shows the co-authorship network connecting the top 25 collaborators of Liji Shen. A scholar is included among the top collaborators of Liji Shen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liji Shen. Liji Shen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Wang, Yizhuo, et al.. (2024). Consideration of stratification in confirmatory trials with time-to-event endpoint. Contemporary Clinical Trials. 141. 107434–107434.
2.
Matsubara, Nobuaki, Kazuo Nishimura, Satoru Kawakami, et al.. (2022). Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis. Japanese Journal of Clinical Oncology. 52(5). 441–448.
3.
Zhu, Liang, Yimei Li, Yongqiang Tang, et al.. (2021). Sample size calculation for recurrent event data with additive rates models. Pharmaceutical Statistics. 21(1). 89–102.
4.
Massard, C., Joaquı́n Mateo, Yohann Loriot, et al.. (2016). Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. Annals of Oncology. 28(1). 90–95.
5.
Azaro, Analía, Jordi Rodón, Jean‐Pascal Machiels, et al.. (2016). A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function. Cancer Chemotherapy and Pharmacology. 78(6). 1185–1197.
6.
Sonpavde, Guru, Menaka Bhor, Debajyoti Bhowmik, et al.. (2015). Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices. Clinical Genitourinary Cancer. 13(4). 309–318.
7.
Rixe, Olivier, Igor Puzanov, Patricia LoRusso, et al.. (2015). Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies. Anti-Cancer Drugs. 26(7). 785–792.
8.
Casanova, Michela, Enis Özyar, Catherine Patte, et al.. (2015). International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents. Cancer Chemotherapy and Pharmacology. 77(2). 289–298.
9.
Evans, Tracey L., Byoung Chul Cho, Katalin Udud, et al.. (2015). Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy. Journal of Thoracic Oncology. 10(8). 1221–1228.
10.
Maison‐Blanche, Pierre, Shaker R. Dakhil, Ari David Baron, et al.. (2014). An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 73(6). 1241–1252.
11.
Lorente, David, Joaquı́n Mateo, Arnoud J. Templeton, et al.. (2014). Baseline neutrophil–lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Annals of Oncology. 26(4). 750–755.
12.
Sonpavde, Guru, et al.. (2014). Impact of number of lines of therapy following docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 32(4_suppl). 223–223.
13.
Soest, Robert J. van, Ellen S. de Morrée, Liji Shen, et al.. (2013). Initial Biopsy Gleason Score as a Predictive Marker for Survival Benefit in Patients with Castration-resistant Prostate Cancer Treated with Docetaxel: Data from the TAX327 Study. European Urology. 66(2). 330–336.
14.
Bahl, Amit, Stéphane Oudard, Bertrand Tombal, et al.. (2013). Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Annals of Oncology. 24(9). 2402–2408.
15.
Halabi, Susan, Chenyu Lin, Eric J. Small, et al.. (2013). Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy. JNCI Journal of the National Cancer Institute. 105(22). 1729–1737.
16.
Pouessel, Damien, Stéphane Oudard, Gwénaëlle Gravis, et al.. (2012). Cabazitaxel dans le cancer de la prostate métastatique résistant à la castration ayant progressé pendant ou après traitement par docétaxel : l'expérience française de l'essai TROPIC. Bulletin du Cancer. 99(7-8). 731–741.
17.
Sartor, Oliver, Stéphane Oudard, Mustafa Özgüroğlu, et al.. (2012). Prognostic factors for survival in the phase III TROPIC trial.. Journal of Clinical Oncology. 30(5_suppl). 102–102.
18.
Sartor, Oliver, Stéphane Oudard, Mustafa Özgüroğlu, et al.. (2011). Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.. Journal of Clinical Oncology. 29(15_suppl). 4525–4525.
19.
Cohen, Ezra E.W., Dominique Rosine, Daniel J. Haraf, et al.. (2007). Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer. International Journal of Radiation Oncology*Biology*Physics. 67(3). 678–684.
20.
Shen, Liji. (2001). An improved method of evaluating drug effect in a multiple dose clinical trial. Statistics in Medicine. 20(13). 1913–1929.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ivo Kocák Breakdown of academic impact, for papers by Susan Feyerabend Breakdown of academic impact, for papers by J Horti Breakdown of academic impact, for papers by Peter De Porre Breakdown of academic impact, for papers by Bryan Selby Breakdown of academic impact, for papers by Matthew M. Cooney Breakdown of academic impact, for papers by William R. Berry Breakdown of academic impact, for papers by Mary Ellen Taplin Breakdown of academic impact, for papers by Luis Fein Breakdown of academic impact, for papers by David Lorente